A Negative Result for Quest Diagnostics

Shares of the lab-services outfit plunged Tuesday after it lost a big contract, though one analyst thinks the sell-off is "overdone"

A negative result from Quest Diagnostics (DGX) is usually a good thing, except when it comes to the company's stock price. Shares of the provider of diagnostic services for the health care industry were pummeled Tuesday after the company said it had lost significant business with health insurance bigshot UnitedHealth (UNH), which accounts for roughly 7% of Quest's revenue.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.